Hims & Hers has risen since November 2024, outperforming the S&P 500. Click here to see why HIMS stock is a Buy.

On Feb. 21, the Food and Drug Administration declared that the shortage was over; Hims & Hers’ stock plummeted and is now down around 50% from its Feb. 19 peak. The company, which made headlines with ...

Hims and Hers' stock fell over 19% in after-hours trading on Monday after its CEO said the company would no longer sell compounded versions of mega-hit weight loss drugs. "We will have to start ...

“We will have to start notifying customers in the coming month or two that they will need to start looking for alternative options on the commercial dosing,” Hims & Hers CEO Andrew Dudum told ...

the future model of health and wellness that centers around the consumer and the consumer alone," CEO Andrew Dudum said on the call Monday. Hims & Hers is focused on bringing disruption to ...

“We will have to start notifying customers in the coming month or two that they will need to start looking for alternative options on the commercial dosing,” Hims & Hers CEO Andrew Dudum told ...

Hims & Hers Health is now reasonably valued after its ... Speaking of its subscriber base, CEO Andrew Dudum said during the Q4 earnings call that hitting 10 million subscribers is "quite in ...

co-founder and CEO of Hims & Hers Health. “In the coming years, we expect to further transform how individuals can improve their health with more comprehensive treatments, technologies that ...

Hims & Hers Health stock declined Friday by about 8% after CEO Andrew Dudum's praise for anti-Israel campus protesters in a social media post last week. Hims & Hers CEO Andrew Dudum said in a ...

Hims & Hers Health shares were headed for their biggest single-day plunge as Wall Street analysts questioned the telehealth provider's lofty sales forecast on Tuesday amid looming restrictions on ...